BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC
BetterInvesting Magazine has announced Amphastar Pharmaceuticals (NASDAQ: AMPH) as its 'Stock to Study' and Medtronic (NYSE: MDT) as its 'Undervalued Stock' for the September 2024 issue. The National Association of Investors Corp. (NAIC) encourages investors to focus on fundamentals and informed decision-making. The magazine's choices are informational and educational, not endorsements. A trial version of BetterInvesting's tools is available for non-members to analyze these stocks. The committee includes several CFA members who review the stocks, emphasizing investor education. Full details will be available in the magazine's September issue.
- Amphastar Pharmaceuticals selected as 'Stock to Study' by BetterInvesting Magazine.
- Medtronic recognized as 'Undervalued Stock' for the September 2024 issue.
- NAIC emphasizes the importance of focusing on fundamentals for long-term wealth.
- BetterInvesting provides trial access to stock selection and analysis tools for non-members.
- Inclusion of CFA members in the review committee enhances the credibility of the stock evaluation.
- The selections are informational and educational, not endorsements, which might limit investor enthusiasm.
- Investors are urged to conduct their own reviews, indicating potential gaps in the provided analysis.
"With GameStop back in the headlines, the siren song of easy money has returned, luring the unschooled down treacherous paths. The National Association of Investors counsels everyday Americans seeking long term wealth to focus on fundamentals and learn to earn," said Ken Zendel, CEO of National Association of Investors Corp. (NAIC), the parent organization of BetterInvesting.
For a refresher on GameStop vs. the fundamentals, read:
https://www.betterinvesting.org/learn-about-investing/investor-education/investing/market-madness-short-selling-short-squeeze
Check the September 2024 issue of BetterInvesting Magazine for more details about the latest stocks. Non-members can utilize the limited, trial version of the BetterInvesting online stock selection and analysis tools to study the investment potential of Amphastar Pharmaceuticals and Medtronic by viewing their fundamental data and applying judgments.
Committee members are Dan Rutter, CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; and Anne Nichols, CFA; Lauren Adams, CFA.
As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.
About BetterInvesting:
BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org
Follow us on LinkedIn and Facebook.
Contact: 877-275-6242
View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-amphastar-pharmaceuticals-inc-and-medtronic-plc-302173374.html
SOURCE NAIC-BetterInvesting
FAQ
What is the 'Stock to Study' for September 2024 in BetterInvesting Magazine?
Which company is BetterInvesting Magazine's 'Undervalued Stock' for September 2024?
Where can I find more details about Amphastar Pharmaceuticals and Medtronic's stock analysis?
Are the stock recommendations in BetterInvesting Magazine endorsed by NAIC?